slides · global inventory
Compare Peers
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 9,820
Current window 7,261-7,290
Pages 328
Rows per page 30
Slide function
7,261-7,290 of 9,820
11
The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the competitive advantage of NXC-201.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Cost Of Inaction1 hit
14
The slide explicitly notes that this is a cross-trial comparison and not a head-to-head study.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Cost Of Inaction1 hit
17
The slide uses a multi-panel line chart with timeline bars to contrast clinical outcomes.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Golden Circle1 hit
20
Includes a disclaimer about cross-trial comparison limitations.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Golden Circle1 hit
21
The slide uses a table structure to contrast patient segments and includes a bar chart representation for patient growth.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Golden Circle1 hit
22
The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Golden Circle1 hit
30
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
31
The slide uses a complex table structure to compare patient demographics and clinical outcomes across three cohorts.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
32
The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red) categorized by prior BCMA treatment status.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
40
The slide highlights specific toxicity data (CRS and ICANS) for a competitor product.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
41
Highlights NXC-201's lower fludarabine dose and Carvykti's longer infusion window.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
42
The table compares four different therapies across four criteria categories: Prior lines of therapy, Toxicity recovery, ECOG, and Measurable disease.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
43
The slide highlights a competitive advantage for NXC-201 regarding patient eligibility.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
55
The slide uses a bar chart comparison to highlight the efficacy gap between established treatments and placebo.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
10
The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the superiority of NXC-201.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
13
The slide uses a bar chart combined with a data table to highlight safety advantages. It includes a disclaimer about cross-trial comparisons.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
16
The slide uses a longitudinal timeline comparison to highlight the superior safety and efficacy profile of NXC-201.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
19
The slide uses a grouped bar chart format to highlight clinical superiority. Includes a disclaimer about cross-trial comparisons.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · ActionLoop · David Goliath1 hit
20
The slide uses a table structure to contrast patient segments and includes a bar chart visualization for patient growth.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · ActionLoop · David Goliath1 hit
21
The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · ActionLoop · David Goliath1 hit
30
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
31
The chart uses a grouped bar structure to compare NXC-201 (green) against competitors (blue/red) across three categories: No BCMA, Yes BCMA, and Overall.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
32
The slide uses a structured comparison table to highlight clinical advantages. It includes a disclaimer about cross-trial comparisons.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
36
The slide highlights specific safety metrics for a competitor's product, likely to contrast with the presenter's own product profile.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
45
The slide uses a scatter plot to map clinical trials and a table to summarize treatment outcomes across lines of therapy.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
58
Highlights NXC-201's lower fludarabine dose and compares infusion timing across therapies.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
61
The slide uses a bar chart comparison to highlight the efficacy gap between established treatments and placebo.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
60
The table compares four different therapies across four criteria categories: Prior lines of therapy, Toxicity recovery, ECOG, and Measurable disease.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
61
The slide highlights that NXC-201 has no exclusion for prior BCMA therapy, unlike the other listed treatments.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
64
The slide uses a bar-grouped chart format to highlight the efficacy gap between established treatments and placebo.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit